DSM creates a joint venture with Nenter & Co to manufacture vitamin E
Category: #business  By Nikita Chaurasia  Date: 2019-01-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

DSM creates a joint venture with Nenter & Co to manufacture vitamin E
  • DSM is likely to acquire a 75 percent stake in the joint venture for about €135 million.
     
  • The new business will exclusively manufacture vitamin E for DSM

The Dutch nutrition firm DSM has reportedly announced that it is planning to form a joint venture with China’s Nenter & Co., Inc. As per trusted sources, DSM is likely to acquire 75 percent stake in the joint venture for about €135 million.

Reportedly, the joint venture will also include all Nenter’s production and related assets for vitamin E. Moreover, both the firms would refurbish and upgrade the facilities to secure a sustainable and supply of vitamin E.

Sources familiar with the development claim that the venture will have a minority shareholding in Nenter’s Shishou facility in Hubei and will acquire and operate vitamin E manufacturing facilities in Jingzhou, China. Reportedly, there will be a profit share deal in place between Nenter and the Heerlen-headquartered firm and the new joint venture would manufacture vitamin E exclusively for DSM.

According to a press release by DSM, Vitamin E has been well-recognized and accepted as nature’s most effective chain-breaking, fat-soluble antioxidant, safeguarding cellular membranes from being damaged by lipid peroxyl radicals. The statement further noted that vitamin E maintains the structural integrity of all tissues and contributes substantially to optimum health. Apart from being an efficacious biological antioxidant, it also contributes to disease resistance of farm animals owing to modulating effects on the immune system.

For the record, DSM currently manufactures vitamin E in Switzerland and the joint venture will reportedly allow the company to simplify its supply chain by expanding manufacturing to the Asia Pacific region.

Reportedly, the joint venture agreement is expected to conclude in the second or third quarter of 2019, subject to several regulatory approvals.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Australian researchers discover anti-parasite drug that kills COVID-19
Australian researchers discover anti-parasite drug that kills COVID-19
By Nikita Chaurasia

Researchers at Monash University, Melbourne, have reportedly announced that they discovered that an anti-parasite medicine can kill the novel strain of the coronavirus (SARS-CoV-2) that has currently brought the world to a standstill. In a study pub...

Trump calls for a $2 trillion budget for U.S. infrastructure growth
Trump calls for a $2 trillion budget for U.S. infrastructure growth
By Nikita Chaurasia

U.S. President Donald Trump has reportedly called for a $2 trillion spending budget to repair the and build new and currently crumbling infrastructure including tunnels, bridges, and roads, seizing on the COVID-19 outbreak as well as interest rates t...

Analytics 4 Life reveals new data backing novel method to predict LVEDP
Analytics 4 Life reveals new data backing novel method to predict LVEDP
By Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiology) 69th Annual Scientific Sessi...